Company Information

  

Address: OSTERGADE 24A, 1  
City: COPENHAGEN 
State:  
Zip Code: 1100 
Telephone: 0114533444242 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

Forward Pharma A/S is a Danish biopharmaceutical company that until recently was actively developing FP187, a proprietary formulation of DMF, for the treatment of several inflammatory and neurological indications, including MS. DMF is an immunomodulator that can be used as a therapeutic to improve the health of patients with immune disorders, including MS. On February 1, 2017, our License Agreement with Biogen became effective. Pursuant to the License Agreement, Biogen paid us a non-refundable cash fee of $1.25 billion. The License Agreement provides Biogen with a co-exclusive license in the U.S. (which will be converted into an exclusive license if certain conditions are met within the time period set forth in the License Agreement), and an exclusive license outside the U.S., to the Company's intellectual property. For more, see "--B. Business Overview--Our Company--Settlement and License Agreement.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
There's no share overview data.

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2016 Leverage 2016
Net Inc/Comm Equity-0.10Total Liab/Total Assets0.04
Net Inc/Total Assets-0.20Total Liab/Inv Cap0.05
Net Inc/Inv Cap-0.21Total Liab/Comm Equity0.02
Pretax Inc/Net SalesNAInterest Coverage RatioNA
Net Inc/Net SalesNACurr Debt/EquityNA
Cash Flow/Net SalesNALTD/EquityNA
SG&A/NetSalesNATotal Debt/EquityNA
Asset Utilization   Liquidity  
Net Receivables TurnoverNAQuick Ratio19.04
Inventory TurnoverNACurrent Ratio19.04
Inventory Day SalesNANet Rec/Curr Assets0.00
Net Sales/Work CapNAInv/Curr AssetsNA
Net Sales/PP&ENA  

Income Statement (Millions)

  12/31/2016 12/31/2015 12/31/2014 6/30/2014
Total Revenues(Net Sales) NA NA NA NA
Cost of Goods Sold NA NA NA NA
Selling & Admin Exps 14.38 15.85 9.15 2.62
Operating Income -55.43 -49.58 -19.70 -7.44
Interest Exp 0.00 0.00 0.42 NA
Pretax Income -54.54 -37.34 -19.27 -8.55
Other Income 0.90 12.24 0.85 -1.11
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -33.34 -37.00 -19.02 -8.50

Balance Sheet (Millions)

Assets 12/31/2016 12/31/2015 12/31/2014 6/30/2014
Cash & Short Term Investments 138.72 93.91 91.59 0.24
Receivables - Total 0.43 0.85 1.10 0.48
Inventories - Total NA NA NA NA
Total Current Assets 139.81 99.80 93.40 2.90
Net Property, Plant & Equipment 0.27 0.35 0.01 0.00
Total Assets 163.14 182.90 225.31 2.90
Liabilities        
Accounts Payable 7.34 6.21 2.92 4.71
Debt in Current Liabilities NA NA NA 0.00
Total Current Liabilities 7.34 6.21 2.92 4.71
Long-Term Debt NA NA NA NA
Total Liabilities 7.34 6.21 2.92 4.71
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock NA NA NA NA
Common Stock 0.80 0.80 0.79 0.31
Retained Earnings -147.40 -131.18 -107.71 -58.89
Treasury Stock NA NA NA NA
Total Stockholders' Equity 155.80 176.69 222.39 -1.81
Total Liabilities and Stockholders' Equity 163.14 182.90 225.31 2.90

Cash Flow Summary (Millions)

Categories 12/31/2016 12/31/2015 12/31/2014 6/30/2014
Net Cash Provided by Operating Activities -34.11 -35.13 -9.46 -4.62
Net Cash Provided by Investing Activities 41.17 43.03 -191.12 NA
Net Cash Provided by Financing Activities 0.11 0.16 237.57 1.91

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/20120.00-22.48--
12/20130.00-15.70--
12/20140.00-19.02--
12/20150.00-37.00--
12/20160.00-33.34--
Growth RatesNaN----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional09/30/173910,33010.95




Report Date : 10/16/2017

Powered By Edgar Online © 2017EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.